Ranbaxy Files Challenge To Controversial Roche Patent For HIV/AIDS Drug
This article was originally published in PharmAsia News
Ranbaxy Laboratories challenged the Indian government's grant of a patent for Roche's drug Valcyte (valganciclovir hydrochloride) for HIV/AIDS infections. The patent grant became controversial within the industry because the Chennai patent office held no hearings on filings in opposition by two non-governmental organizations. Ranbaxy asserts the Valcyte formula had not been shown to have any more efficacy than already known. Cipla also said it would challenge the patent. (Click here for more
You may also be interested in...
The US FDA issued only one device-related close-out letter in October.
Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.